Egwuenu EJ, Fong AY, Pilowsky PM. Intrathecal melanin-concentrating hormone reduces sympathetic tone and blocks cardiovascular reflexes. Am J Physiol Regul Integr Comp Physiol 303: R624 -R632, 2012. First published July 18, 2012 doi:10.1152/ajpregu.00215.2012.-Melanin-concentrating hormone (MCH) is a neuropeptide that acts to increase feeding behavior and decrease energy expenditure. The role of MCH in central cardiorespiratory regulation is still poorly understood. Experiments were conducted on urethane-anesthetized, vagotomized, and artificially ventilated male Sprague-Dawley rats (n ϭ 22) to ascertain whether MCH modulates sympathetic vasomotor tone, as well as barosympathetic, chemosympathetic, and somatosympathetic reflexes at the level of the spinal cord. Intrathecal injection of 10 l of MCH produced a dose-dependent hypotension, bradycardia, and sympathoinhibition. Peak response was observed following administration of 1 mM MCH, causing a decrease in mean arterial pressure of 39 Ϯ 2 mmHg (P Ͻ 0.001), splanchnic sympathetic nerve activity of 78 Ϯ 11% (P Ͻ 0.001), and heart rate of 87 Ϯ 11 beats per minute (bpm) (P Ͻ 0.01). The two peaks of the somatosympathetic reflex were decreased by intrathecal MCH, 7 Ϯ 3% (P Ͻ 0.01) and 31 Ϯ 6% (P Ͻ 0.01), respectively, and the spinal component of the reflex was accentuated 96 Ϯ 23% (P Ͻ 0.05), with respect to the baseline for MCH, compared with the two peaks and spinal component of the somatosympathetic reflex elicited following saline injection with respect to the baseline for saline. MCH decreased the sympathetic gain to 120 s of hyperoxic hypercapnea (10% CO 2 in 90% O2) and to 10 -12 s poikilocapneic anoxia (100% N2) from 0.74 Ϯ 0.14%/s to 0.23 Ϯ 0.04%/s (P Ͻ 0.05) and 16.47 Ϯ 3.2% to 4.35 Ϯ 1.56% (P Ͻ 0.05), respectively. There was a 34% decrease in gain and a 62% decrease in range of the sympathetic baroreflex with intrathecal MCH. These data demonstrate that spinal MCH blunts the central regulation of sympathetic tone and adaptive sympathetic reflexes. neuropeptide; cardiovascular physiology; neurophysiology; melaninconcentrating hormone; blood pressure THERE IS A GROWING BODY of evidence showing that peptides, such as pituitary adenylate cyclase activating polypeptide (PACAP), galanin, orexin A, somastostatin, and bombesin perform neurotransmitter and neuromodulatory functions in cardiorespiratory regulation (11, 14, 42, 46, 51) .
THERE IS A GROWING BODY of evidence showing that peptides, such as pituitary adenylate cyclase activating polypeptide (PACAP), galanin, orexin A, somastostatin, and bombesin perform neurotransmitter and neuromodulatory functions in cardiorespiratory regulation (11, 14, 42, 46, 51) .
Melanin-concentrating hormone (MCH) is a 19-amino acid peptide derived from a precursor peptide, prepro-MCH (7, 19) . MCH neurons are located exclusively in the hypothalamus. There are two known receptors for MCH, MCH 1 , and MCH 2 (2) . Both MCH 1 and MCH 2 are G protein-coupled receptors (GPCR). MCH 1 was discovered from studies of orphan GPCR (4, 12, 22, 40, 44) and is identical to the somastostatin-like orphan receptor, SLC-1 (18, 20, 21) . MCH 2 is expressed in humans and dogs but not in rodents (49) . MCH is hypothesized to be involved in energy homeostasis on the basis of its ability to stimulate feeding (37, 38) . Transgenic mice of the Friend virus B-type genetic background, produced to overexpress the MCH gene, develop obesity and insulin resistance (22) , supporting a role for MCH in energy homeostasis. In addition to its role in energy homeostasis, MCH also regulates the autonomic nervous system. Chronic intracerebroventricular infusion of MCH induces bradycardia and decreases the mean arterial pressure (26) . MCH microinjection into the medial nucleus tractus solitarius (NTS) elicits both a hypotensive and bradycardic response (9) . MCH 1 knockout mice exhibit a tachycardia that is reversed by blocking adrenergic receptors (3) , suggesting that deficiency of central MCH 1 increases sympathetic tone and/or decreases vagal tone compared with the wild-type mice (3) .
Expression of MCH and MCH 1 has been demonstrated in vagal afferent neurons with robust expression of both MCH and MCH 1 in rat nodose ganglion during the fasted state and weak expression during the fed state (10) . In addition, primary vagal afferents have their central terminals mainly in the NTS, with the cardiac and pulmonary afferent principally in the lateral subnuclei of the NTS (5) . Although the exact mechanisms as to how MCH would affect this vagal network are yet to be elucidated, the MCH-related vagal neurochemistry and anatomical connections raise the possibility that MCH might play a role in the parasympathetic regulation of cardiovascular activity.
Central MCH neurons are found predominantly in the lateral hypothalamus (LH) and the zona incerta (7, 45) . In the LH, MCH-positive neurons are organized into two main clusters; one cluster is situated in the perifornical region, while the other is situated in the peripeduncular region (19) . Sympathetic-premotor neurons in the hypothalamus also express MCH (19) , and MCH-immunoreactive fibers can be found in sparse amounts in the intermediolateral cell column (IML) of the spinal cord (6) . The IML of the thoraco-lumbar spinal cord is the region in which most sympathetic preganglionic neurons (SPN) are located (32, 48) . SPN are the final central neurons in the sympathetic efferent pathway to the periphery.
Since MCH-containing neurons project directly to the IML of the spinal cord, we hypothesized that activation of MCH receptors in the spinal cord would produce a decrease in sympathetic vasomotor tone and may also affect autonomic reflex function.
The aim of this study was to ascertain the effects of intrathecal MCH on mean arterial pressure (MAP), splanchnic sympathetic nerve activity (SNA), central respiratory activity as measured from the phrenic nerve, and their responses to adaptive reflexes, including the barosympathetic, chemosympathetic, and somatosympathetic reflexes.
METHODS
All animal experiments were carried out in compliance with the guidelines of the Australia Code of Practice for the Care and Use of Animals for Scientific purposes and were approved by the Animal Ethics Committee of Macquarie University (Sydney, Australia).
Surgical preparation. Electrophysiology experiments were conducted as previously described (13, (27) (28) (29) (30) . Male Sprague-Dawley rats (n ϭ 22, 350 -650 g) were anesthetized with urethane (1.2-1.4 g/kg ip). Additional urethane (20 -30 mg iv) was given as required after assessment of anesthetic depth by monitoring changes in arterial pressure (an increase greater than 10 mmHg) following a hind paw pinch. Cannulation of the right and left jugular vein, as well as the right carotid artery, was done using polyethylene tubing [PE-50, internal diameter (ID) ϭ 0.58 mm and external diameter (ED) ϭ 0.96 mm] to administer fluid and drugs and to measure arterial pressure, respectively. Temperature was monitored with a rectal thermometer and maintained at 37 Ϯ 0.5°C using a feedback-controlled heating blanket (Harvard Apparatus, Holliston MA). The left splanchnic sympathetic nerve and the left phrenic nerve were exposed via a dorsolateral approach and cut distally with the proximal end of both nerves secured with a silk thread to allow recording of efferent nerve activity. In another group of animals, the left sciatic nerve was also exposed and cut distally to permit electrical stimulation. For the duration of the surgical preparation, the isolated nerves were covered with cotton wool soaked in saline to prevent desiccation.
Rats were mounted on a stereotaxic frame, and the occipital bone and atlanto-occipital membrane were exposed. The membrane was cut, and an intrathecal catheter (PE tubing ID ϭ 0.4 mm and OD ϭ 0.8 mm) was inserted into the subarachnoid (intrathecal) space and passed caudally to the level of T5-T7. The catheter was noted as patent by the outflow of cerebrospinal fluid. The cervical vagi were cut, and the rat was paralyzed with pancuronium bromide (initial bolus of 0.8 mg iv and then 0.4 mg/h iv) and ventilated artificially with oxygen-enriched room air. The end-tidal CO2 level was maintained at 4.0 Ϯ 0.5%. Arterial blood gases were monitored, and ventilation was regulated to keep the blood pH and PaCO 2 within the range (pH: 7.35 Ϫ 7.45, PaCO 2 40.7 Ϯ 0.7 mmHg). An intravenous infusion was maintained throughout the experiment to ensure adequate hydration [5% glucose in water (1.0 Ϫ 2.0 ml/h)]. Additional intravenous urethane (20 -30 mg) was given if anesthetic depth was considered subpar when a hind paw pinch produces an increase in arterial pressure greater than 10 mmHg. Recordings from the isolated nerves were made using bipolar silver wire electrodes immersed in a pool of liquid paraffin oil to prevent the nerves from drying and for electrical insulation. A three-lead ECG recording was also obtained. The neurograms were amplified (ϫ10,000; CWE, Ardmore, PA), band-pass filtered (0.1-2 kHz), and sampled at 3 kHz (1401 plus, Cambridge Electronic Design Cambridge, UK). The recordings were analyzed using Spike2 software (v7; Cambridge Electronic Design, Cambridge, UK).
Intrathecal drug administration. Intrathecally administered (MCH: 0.1, 0.3, 0.5, 1.0, and 2.0 mM) and vehicle (0.9% saline; pH 7.4) were given in a total volume of 10 l using a 25 l Hamilton syringe. The intrathecal catheter volume was between 6 and 8 l, and the injections were made over 15-20 s.
Activation of sympathetic reflexes. Reflexes were evoked as previously described (27, 42) . The somatosympathetic reflex was activated by electrical stimulation (5-10 V, 100 sweeps, 0.2-ms pulses at 1 Hz) of the sciatic nerve using bipolar silver-wire electrodes. Sympathetic baroreflex curves were obtained by injecting sodium nitroprusside (SNP; 10 g/kg), followed by phenylephrine (PE; 10 g/kg) through two separate venous lines. The peripheral chemoreflex was elicited in the rat with 100% nitrogen for 10 -12 s, and the central chemoreflex was stimulated with 10% CO2 in 90% oxygen for 120 s.
Data acquisition and analysis. Nerve recordings were rectified and smoothed with a 1 s time constant for splanchnic sympathetic nerve activity (sSNA) and 50 ms for phrenic nerve activity (PNA). For sSNA, the minimum activity post mortem was taken as zero and subtracted from the sSNA prior to analysis. Analysis was undertaken offline using Spike2 (version 7.0. CED, Cambridge UK). Baseline values were obtained for MAP, sSNA, heart rate (HR), phrenic nerve frequency (PNf), phrenic nerve amplitude (PNamp) by averaging 120 s of data 5 min before injection. The peak responses for MAP, HR, and PNf were expressed as changes in absolute values, while sSNA and PNamp were both expressed as a percentage change. Changes in MAP, HR, sSNA, and PNA are expressed as means Ϯ SE. A time course analysis for ⌬MAP, ⌬SNA, and ⌬HR was obtained by averaging 60 s of data every 5 min for 25 min starting from the time of injection, and time course changes were compared using a two-way ANOVA with Bonferrroni's correction.
To analyze the somatosympathetic reflex, the sSNA was normalized between sSNA before saline (100%) injection and the sSNA post mortem (0%). Peristimulus waveform averaging was used to analyze the sSNA response to sciatic nerve stimulation. The peak responses for saline and MCH were obtained following sciatic nerve stimulation and expressed as a percentage change from their respective baselines. The parameters describing the sSNA response to hypercapnea (inhalation of 10% CO 2 in O2 for 120 s), hypoxia (inhalation of 100% N2 for 10 -12 s), and the sympathetic baroreflex (10 g/kg iv SNP followed by 10 g/kg PE) were obtained from the slope (gradient) of a Boltzmann sigmoid fit applied to an XY plot of SNA (%) vs. time (s) and SNA (%) vs. MAP (mmHg), respectively. The change in SNA with MAP at the steepest part of the sigmoid curve (Slope50) was taken as a measure of sympathetic barosensitivity, and the change in the plot of SNA vs. time at the steepest part of the curve was considered a measure of chemosensitivity. Results of all data were exported to GraphPad Prism (version 5.0; GraphPad, La Jolla, CA), and Student's t-test was used to analyze peak responses. Results were expressed as means Ϯ SE and considered significant if P Ͻ 0.05.
Drugs. The drugs used were MCH (mol wt ϭ 2,386) (Selleck Chemicals, Houston, TX); urethane, PE, SNP (Sigma-Aldrich, St. Louis, MO), pancuronium bromide (AstraZeneca, North Ryde, NSW, Australia), and normal saline 0.9% NaCl in water. MCH was dissolved in normal saline. Normal saline, PE, and SNP were prepared in deionized water and urethane was dissolved in 0.9% NaCl.
RESULTS

Effect of intrathecal MCH on the cardiovascular system.
MCH produced a dose-dependent decrease in MAP, sSNA, and HR (Fig. 1, A and B) . On the basis of the dose-response result, 1 mM was used in other parts of the study. The peak response was obtained with the injection of 1 mM MCH, resulting in a decrease in MAP, HR, and sSNA of 39 Ϯ 2 mmHg (n ϭ 5; P Ͻ 0.001), 87 Ϯ 11 bpm (n ϭ 5; P Ͻ 0.01), and 78 Ϯ 11% (n ϭ 5; P Ͻ 0.001), respectively ( Fig. 2A) . The response started about 5 min after the intrathecal injection of MCH. In contrast, injection of saline (vehicle) into the spinal cord produced no significant change in MAP (2 Ϯ 1 mmHg; n ϭ 5), SNA (3 Ϯ 1%, n ϭ 5), and HR (6 Ϯ 1 bpm, n ϭ 5) from baseline values ( Fig. 2A) .
Effect of MCH on the respiratory system. There was no significant change in PNA (n ϭ 5), PNf, and PNamp following intrathecal injection of MCH (Fig. 3, A and B) .
Effects of MCH on the somatosympathetic reflex. After injection of saline, intermittent stimulation of the sciatic nerve elicited a characteristic two-peak excitatory response. The amplitudes of the spinal component, the first and second excitatory peaks of the reflex following the intrathecal injection of saline (with respect to baseline for saline) were ϩ23 Ϯ 5%, ϩ143 Ϯ 25%, and ϩ113 Ϯ 15% (n ϭ 5), respectively (Fig. 4) .
However, basal sSNA decreased after intrathecal MCH administration from 99 Ϯ 1% to 27 Ϯ 6% (n ϭ 5; P Ͻ 0.001). Intrathecal administration of MCH enhanced the spinal component of the reflex, producing an increase of 96 Ϯ 23% (n ϭ 5; P Ͻ 0.05) but blunted the effect of the first (7 Ϯ 3% n ϭ 5; P Ͻ 0.01) and second peaks, 31 Ϯ 6% (n ϭ 5; P Ͻ 0.01) compared with the new baseline after MCH injection (Fig. 4, A-D) .
Effect of MCH on the peripheral chemoreflex. A sigmoid curve fit was used to assess the response to anoxia. Injection of MCH caused a significant decrease in the sensitivity (gain) of the sympathoexcitatory response to anoxia (ventilation with 100% N 2 for 10 -12 s), 4.35 Ϯ 1.56%/s (n ϭ 3; P Ͻ 0.05) when compared with the response to anoxia following the injection of vehicle (0.9% saline) at 16.47 Ϯ 3.21%/s (Fig. 5, A and B) . There was no significant change in the upper and the lower limit or in the range of the response after MCH injection. MCH produced no significant change in the response of the phrenic nerve activity. PNf and PNamp response were unaffected by MCH. 
Effect of MCH on central chemoreflex.
Central chemoreceptors were stimulated by administering 10% CO 2 in oxygen for 120 s. A sigmoid curve fit was used to assess the response to hypercapnea. Injection of MCH induced a significant decrease in the sensitivity (gain) of the sympathetic nerve activity to hypercapnea, 0.23 Ϯ 0.04%/s (n ϭ 5; P Ͻ 0.05) compared with the vehicle, 0.74 Ϯ 0.14%/s (Fig. 5, C and D) . There was no significant change in the maximum and minimum limits, or in the range of the response induced by MCH compared with saline injection. The PNA (PNf and PNamp) response to hypercapnea was unaffected by MCH.
Effects of MCH on the sympathetic baroreflex. A change in MAP was induced by sequential injection of SNP followed by PE to determine whether MCH affected the sympathetic baroreflex. MCH caused a significant inhibition from Ϫ2.43 Ϯ 0.23 to Ϫ1.58 Ϯ 0.12%/mmHg (n ϭ 5; P Ͻ 0.01) of the maximum gain, and a decrease in the range of response from 83.8 Ϯ 6 to 31.59 Ϯ 12.66% (n ϭ 5; P Ͻ 0.05) compared with the response to saline injection (Fig. 6, A-C) . There was no significant change in the upper and lower plateau of the response.
DISCUSSION
The key findings of this study are that intrathecal injection of 1.0 mM MCH causes 1) a marked hypotension and bradycardia; 2) a significant decrease in sympathetic nerve activity; 3) an accentuation of the spinal peak, abolition of the first peak, and attenuation of the second peak of the somatosympathetic reflex; 4) a decreased response of the sympathetic baroreflex by blunting its sensitivity and reducing the range of its response; and 5) an attenuation of the excitatory response of the sympathetic but not the phrenic response to both the central and peripheral chemoreflex. There are accumulating data that indicate that MCH plays a significant role in the regulation of energy metabolism. Mice that lack MCH, in addition to being hypophagic and lean, are also observed to have an increase in metabolic rate (43) . The increase in sympathetic activity in cold-exposed rats was augmented by blocking MCH expression (34) . MCH is implicated in mood disorders, such as depression and anxiety; the administration of a specific MCH receptor antagonist produced antidepressant and anxiolytic effects (8) .
This is the first study to assess the role of intrathecal MCH on PNA, basal cardiovascular variables, cardiorespiratory reflexes, and the responses of the cardiovascular system and the sympathetic nerve activity to spinal injection of MCH. Previous studies have examined the hypotensive and bradycardic effects during chronic intracerebroventricular infusion of MCH (26) and the depressor and bradycardic responses to the microinjection of MCH in the medial NTS (9) . These results suggest that MCH plays a role in many aspects of the central regulation of sympathetic nerve activity and cardiovascular function. MCH-immunoreactive fibers are present in sparse amounts in the IML and the lumbar ventral horn of the spinal cord (6) . The SPN in the IML are the final central sympathetic neurons in the output to vasomotor pathways. The main excitatory neurotransmitter regulating SPN is L-glutamate (35) , but there is now considerable evidence to suggest that the excitatory effect of L-glutamate is modulated by a host of neuropeptides like somatostatin, galanin, bombesin, PACAP, and orexin (11 14, 36, 42, 46, 51) . The MCH receptors MCH 1 and MCH 2 are expressed in various tissues, especially the brain and spinal cord, but MCH 2 is present in humans, not in rodents (17, 39) . MCH 1 couples to G␣i and G␣q proteins to activate second messengers (40) . MCH 1 coupling to G␣i inhibits forskolin-induced cAMP accumulation, by inhibiting the activity of adenylyl cyclase. In the presence of MCH 1 -induced suppression of cAMP production, neuronal inhibition ensues. MCH 1 coupling to G␣q activates phospholipase C, which hydrolyzes phosphoinositide-4,5-bisphosphate to produce inositol 1,4,5-triphosphate (IP 3 ) and diacylglycerol. IP 3 then triggers the intracellular release of Ca 2ϩ . The EC 50 values show that MCH coupling to G␣i is stronger than that to G␣q (40) . It is plausible that while the net effect of MCH is inhibitory, transient increases in intracellular Ca 2ϩ concentration, produce a brief excitatory response that may counter the inhibitory effects of MCH. The delay of 4 -5 min between injection and response may be due to a number of factors, including the time taken to reach the receptors and the slowly developing responses that are consistent with GPCR. Such delays are entirely consistent with our previous studies with peptides. (42, 51, 52) . The decrease in intracellular cAMP may explain the depressor and bradycardic effects of intrathecal MCH administration.
In contrast, orexin-containing neurons found in the lateral hypothalamus in the same region as MCH neurons, have been shown to increase MAP, SNA, and HR following exogenous orexin intrathecal injection (42) . Orexin microinjection in the medullary raphe has also been shown to increase heart rate and arterial pressure (24) . These different responses support the notion that cardiovascular changes are the summation of the individual effects of multiple neurotransmitters. MCH attenuates barosensitivity. Axons of barosensitive rostral ventrolateral medulla (RVLM) neurons descend to activate vasomotor and preadrenal (noradrenergic) chromaffin cells (35, 36) . Here, we report a significant decrease in sensitivity in the baroreflex response, as well as a significant decrease in the range of activity. It is not clear how MCH attenuates barosensitivity, but possible mechanisms may include 1) modulation of barosensitivity at the spinal level by indirectly accentuating the inhibition of descending excitatory pathways that are tonically active (35) or 2) directly exciting a spinal inhibitory pathway (50) .
Chemosensitivity is decreased by MCH. Both hypoxia and hypercapnea trigger reticulospinal excitatory neurons in the RVLM that send projections to the SPN. These reticulospinal projections are glutamatergic and are monosynaptic to the SPN; therefore, stimulation of the peripheral or central chemoreflex produces a reversible sympathoexcitation. Here, we report that intrathecal MCH attenuated the sensitivity of the sympathetic response to both peripheral and central chemostimulation. The precise mechanism for this response is still unknown, but it has been demonstrated that MCH reduces the amplitude and frequency of small excitatory postsynaptic currents in neurons of the LH and may modulate the presynaptic release of glutamate, as well as the postsynaptic glutamate receptors (16) . Therefore, MCH may dampen glutamatergic transmissions of the monosynaptic reticulospinal neurons, thus attenuating the sympathetic response of the chemoreflex.
MCH suppresses the somatosympathetic reflex. The somatosympathetic reflex is relayed to SPN after processing and integration in the RVLM (25, 27, 47) . In this study, activation of the MCH receptor accentuated the spinal component of the reflex, abolished the first peak, and significantly decreased the second peak. This raises the possibility that MCH may modulate the somatosympathetic reflex at the spinal level. It has been demonstrated that MCHimmunoreactive fibers are clustered mainly in laminae I, III, and IV in the dorsal horn of the spinal cord (6), laminae that have fibers that evoke reflexes via myelinated and unmyelinated somatic afferents (31, 41) . This increases the likelihood that MCH 1 may be activated to inhibit dorsal horn neurons that are part of a somatosensory pathway. The fact that the spinal component of the reflex was accentuated suggests that the overriding and dominant supraspinal contribution of the reflex is inhibited, as evidenced by the marked decrease of the first and second peaks.
In conclusion, this study shows that MCH has a direct central sympathoinhibitory effect when administered intrathecally. MCH decreased MAP, sSNA, and HR when injected in the spinal cord; effects that are mediated by the activation of MCH 1 . MCH also depressed physiological responses to adaptive reflexes. These results show that MCH plays a role in the central regulation of the autonomic nervous system and, consequently, central cardiovascular function regulation.
Perspectives and Significance
The findings we have reported here support the theory that chemical coding in the spinal cord and brain stem regulates cardiorespiratory function, as evidenced by the differential responses observed when peptides are injected into the spinal cord (15, 42, 51, 52) , and are part of an extensive and ongoing study in our laboratory. Stimulation of areas in the LH with MCH-containing neurons causes depressor effects (1, 33) , but stimulation of nearby orexin-containing neurons in the LH produces pressor responses (1) . This fine balancing act lends further weight to the theory that sympathetic activity is the summation of the effects of several peptides and neurotransmitters. Further study is indicated to properly delineate the exact neuronal network mechanisms through which MCH evokes its effects, and under what physiological and/or pathological conditions the effects of MCH are most potent. These future studies may hold the promise of MCH being used as a treatment modality for cardiovascular disorders such as hypertension and heart failure.
